Toenail fungus, medically known as onychomycosis, is a common infection of the nail caused by fungi. It often starts as white or yellow spots under the tip of the toenail and can progress to cause nail discoloration, thickness, brittleness, and even nail separation from the nail bed. Onychomycosis is especially common in older adults, affecting nearly 50% of people over age 70.
In some cases, untreated toenail fungus can lead to permanent nail damage and pain. The infection may also spread to other nails or the surrounding skin, potentially causing foot pain or secondary bacterial infections like cellulitis. For these reasons, many people seek treatment to eliminate the fungus and restore healthier nails. Two of the most common topical prescriptions for nail fungus are ciclopirox and Jublia (efinaconazole).
But which is more effective? Understanding how they work, what clinical studies show, and who benefits most from each option helps set realistic expectations.
How do ciclopirox and Jublia treat toenail fungus?
Ciclopirox is a broad-spectrum antifungal medication that has been used for decades to treat fungal infections of the skin, scalp, and nails.
For nail fungus, it is formulated as an 8% nail lacquer with brand names like Penlac that is applied directly to the affected nails. That’s why it’s often described as a prescription nail polish for fungus. When applied, the liquid solvents evaporate and leave behind a film with around 35% concentration of the drug.
Ciclopirox was approved by the FDA in 1999, becoming the first prescription topical treatment for onychomycosis. It works by blocking minerals that fungi need to survive, such as iron. Without these minerals, the fungus cannot function properly and eventually dies.
Jublia is the brand name for efinaconazole 10%, a newer topical antifungal solution specifically designed to treat toenail fungus. It was approved by the FDA in 2014, making it a more recent option compared to ciclopirox.
Efinaconazole is a triazole antifungal agent, like fluconazole or itraconazole. It works by preventing fungi from forming their protective outer membrane, which causes the fungal cells to develop weak cell membranes and ultimately die off.
Jublia is formulated as a clear solution created to enhance penetration into the nail and surrounding skin. The solution has a low surface tension and doesn’t bind strongly to keratin, which allows it to spread broadly and seep into the nail plate and nail bed more effectively.
Which is more effective for toenail fungus, ciclopirox or Jublia?

Jublia has been shown to be more effective overall than ciclopirox for treating toenail fungus.
In the clinical trials of ciclopirox nail lacquer, only about 5.5% to 8% of patients achieved a complete cure. This typically means that, at the end of treatment, the toenail looked completely healthy and lab tests found no trace of the fungus.
When looking at its mycological cure rates, which means eliminating the fungus according to lab tests, but the nail isn’t perfectly normal in appearance, ciclopirox resulted in a 29-36% mycological cure rate.
Jublia shows significantly better outcomes. In its trials, Jublia showed a mycological cure rate of around 53-55%. More impressively, the complete cure rate with Jublia was about 15-18% of patients in those studies.
That is roughly two to three times higher than the complete cure rate seen with ciclopirox in studies.
Why does Jublia perform better?
One reason why Jublia works better as a topical treatment is that it penetrates the nail well and continues to work inside the keratin-rich nail, where the fungus lives. Many antifungal drugs get stuck to keratin near the surface, which prevents enough medicine from reaching the fungus.
In one study, about 14% of efinaconazole remained available to act against fungus, compared to only 0.7% for ciclopirox.
In lab tests, efinaconazole was able to pass through the entire thickness of human nails and stop fungal growth underneath the nail. It also killed common nail-fungus organisms even when keratin was present, performing better than ciclopirox.
It’s also worth noting that adherence or patient compliance dramatically affects ciclopirox’s effectiveness. The medication must be applied every single day for many months. Missing applications or stopping too early will reduce the already modest chance of success. Additionally, regular nail care is part of the treatment, which includes trimming the nails short and filing the top surface to help ciclopirox penetrate.
Cost comparison of ciclopirox and Jublia
Ciclopirox is the budget-friendly option, often covered by insurance and costing very little even if paid in cash. Jublia is far more expensive and may not be covered.
Ciclopirox nail lacquer is available as a generic medication, so it’s relatively inexpensive. A bottle, usually around 6 mL, can cost around $118.82, but many pharmacies offer it for even less. In addition, insurance often covers ciclopirox because it’s generic and considered a first-line topical treatment.
Jublia, being a brand-name only medication, is much more expensive. Without insurance or savings programs, a 4 mL bottle of 10% Jublia may cost about $923.52 at certain pharmacies. An 8 mL bottle can cost approximately $1,844.84.
Since treatment runs for 48 weeks, the total expense could run many thousands of dollars. Many insurance plans do not cover Jublia, or they require prior authorization. It’s not always on formularies, or insurers might insist that you try cheaper alternatives first, like ciclopirox, or even an oral antifungal.
Application and treatment duration for ciclopirox vs. Jublia
Using ciclopirox versus using Jublia day-to-day involves some different steps, but both require consistency. Jublia offers a bit more convenience, while ciclopirox, being a lacquer, requires more maintenance.
Here’s how they differ in application and treatment:
Treatment length
The standard recommended course for ciclopirox and Jublia is 48 weeks or approximately 11-12 months of daily use. This lengthy duration is necessary because of the slow growth of toenails.
A toenail, especially the big toe, can take up to 18 months to grow out fully from base to tip. To truly eliminate the fungus, you have to treat through an entire nail regrowth cycle so that the new, fungus-free nail can replace the old infected nail.
Stopping too early, even if the nail looks better halfway through, could leave some fungus alive, and the infection might rebound.
Application routine
The daily routine differs slightly between the two.
Ciclopirox
Jublia
Here’s how to apply Jublia:
Jublia doesn’t create a hard film layer, so you do not need to wash it off or remove it at any point. Some patients often find this cleaner and more convenient, as it doesn’t discolor the nail like ciclopirox lacquer might.
Use with nail polish
It’s advised not to use cosmetic nail polish or pedicures during treatment with either ciclopirox or Jublia. Any coating on the nail could interfere with the penetration of the medication.
That said, studies found that nail polish does not greatly reduce how well efinaconazole passes through the nail, so you can cover up the appearance of nail fungus while using Jublia. Ciclopirox, on the other hand, definitely should not be combined with nail polish because it forms its own polish-like film and needs direct contact with the nail.
However, as a precaution and best practice, most doctors will recommend avoiding nail polish with either medication until the fungus is treated.
Side effects and safety of ciclopirox vs. Jublia
Both ciclopirox and Jublia have favorable safety profiles. Unlike oral antifungals, which carry risks like liver enzyme elevations or drug interactions, ciclopirox and Jublia are applied locally and have very little absorption into the bloodstream. This means they do not typically cause body-wide side effects.
Routine blood tests like liver function tests are also not required when using ciclopirox or Jublia, which is a relief to many patients who are hesitant about oral medications.
The most commonly reported side effects of both medications are ingrown toenails and minor skin irritation at the application site, such as:
-
- redness
- itching
- slight burning sensation around the nail
Allergic reactions are very rare but possible with any topical. If you develop a severe rash, swelling, or other signs of allergic reaction after applying these, you should discontinue and seek medical advice.
Bottom line
When comparing ciclopirox and Jublia for toenail fungus, the evidence suggests that Jublia (efinaconazole) is more effective overall, with roughly double or more the cure rates achieved by ciclopirox in clinical trials. Jublia’s advanced formulation allows it to penetrate the nail and eradicate fungus more efficiently, leading to higher odds of clearing the infection. However, ciclopirox remains a valuable option due to its affordability and ease of access.
Whichever you start with, use it exactly as directed and be consistent. If one treatment doesn’t work, consult your doctor about other options or a combination approach. Toenail fungus can certainly be stubborn, so you need to be persistent and use the right treatment strategy for your situation. Always follow medical advice and ensure an accurate diagnosis before starting treatment.
Frequently Asked Questions
Sources
Gupta AK. Ciclopirox nail lacquer topical solution 8%. Skin Therapy Lett. 2000;6(1):1-5. PMID: 11027420. https://pubmed.ncbi.nlm.nih.gov/11027420/
Faraz Yousefian, DO; Ciaran Smythe, DO; Haowei Han, DO; Boni E Elewski, MD; and Mark Nestor MD, PhD. (2024). Treatment options for onychomycosis: efficacy, side effects, adherence, financial considerations, and ethics. JCAD – The Journal of Clinical and Aesthetic Dermatology. https://jcadonline.com/treatment-options-for-onychomycosis-efficacy/
Kristine Hoffman DPM. (2014, October 1). A closer look at a new topical option for onychomycosis. HMP Global Learning Network. https://www.hmpgloballearningnetwork.com/site/podiatry/blogged/closer-look-new-topical-option-onychomycosis
Sugiura, K., Sugimoto, N., Hosaka, S., Katafuchi-Nagashima, M., Arakawa, Y., Tatsumi, Y., Siu, W. J., & Pillai, R. (2014). The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment. Antimicrobial Agents and Chemotherapy, 58(7), 3837–3842. https://doi.org/10.1128/aac.00111-14
Ciclopirox topical: MedlinePlus drug information. (n.d.). https://medlineplus.gov/druginfo/meds/a604021.html
Abney SE, Ijaz MK, McKinney J, Gerba CP. Laundry Hygiene and Odor Control: State of the Science. Appl Environ Microbiol. 2021 Jun 25;87(14):e0300220. doi: 10.1128/AEM.03002-20. Epub 2021 Jun 25. PMID: 33962979; PMCID: PMC8231443. https://pmc.ncbi.nlm.nih.gov/articles/PMC8231443/





